Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effectiveness of Bbibp-Corv Vaccine in Preventing Sars-Cov2 Infection and Severe Outcomes in People Living With Multiple Sclerosis: A Population-Based Study Publisher Pubmed



Barzegar M1, 2 ; Manteghinejad A3 ; Afsharisafavi A2, 4 ; Mirmosayyeb O1, 2 ; Nasirian M5 ; Bagherieh S2 ; Mazaheri S1, 2 ; Rahimi M1, 2 ; Zabeti A6 ; Javanmard SH7 ; Shaygannejad V1, 2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Cancer Prevention Research Center, Omid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran
  5. 5. Department of Biostatistics and Epidemiology, Faculty of Health, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. University of Cincinnati, Cincinnati, OH, United States
  7. 7. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Multiple Sclerosis and Related Disorders Published:2023


Abstract

Background: The objective of the present study was to estimate the effectiveness of the BBIBP-CorV vaccine (VE) in preventing SARS-CoV-2 infection, related hospitalization, and death among people living with multiple sclerosis (PLWMS). Methods: In this population-based retrospective observational study, data on all PLWMS, vaccination, SARS-CoV-2 tests, hospitalization, and deaths were collected in Isfahan, Iran between February 9, 2021, and November 4, 2021. We estimated the hazard ratio between vaccinated (partially and fully) and unvaccinated groups using the Andersen-Gill extension of the Cox proportional hazards model. We also performed Cox proportional hazards analysis to identify risk factors for breakthrough infection and COVID-19-related hospitalization in fully-immunized group. Results: Of the 9869 PLWMS, 1368 were in partially-vaccinated group, 4107 were in the fully-vaccinated group, and 3794 were in the unvaccinated group. In the partially-vaccinated group, the estimated VE against COVID-19 infection was 39.3% (16%, 56.1%), hospitalization was 64.9% (1.3%, 87.5%), and mortality was 92.7% (88.8%, 100%). The respective results for the fully-vaccinated group were 63.9% (56%, 70.3%), 75.7% (57.5%, 86.1%), and 100%. Progressive MS was independently associated with a greater risk of breakthrough infection (HR=1.952, 95%CI: 1.174–3.246, p = 0.010). Older adults (≥50 years vs. 18–49 years, HR=3.115, 95%CI: 1.145–8.470, p = 0.026) and those on rituximab (HR=7.584; 95% CI: 1.864–30.854; p = 0.005) were at an increased risk of COVID-19-related hospitalization. Conclusion: This study showed that two doses of the BBIBP-CorV vaccine can effectively prevent COVID-19 infection and hospitalization among PLWMS. Old PLWMS and those who treating with rituximab are at increased risk of hospitalization after receiving two doses of the vaccine. © 2023
Related Docs
View other Related Docs
1. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
2. Effect of Multiple Sclerosis Disease-Modifying Therapies on the Real-World Effectiveness of Two Doses of Bbibp-Corv (Sinopharm) Vaccine, Journal of the Neurological Sciences (2023)
3. Multiple Sclerosis Disease-Modifying Therapies and Covid-19 Vaccines: A Practical Review and Meta-Analysis, Journal of Neurology, Neurosurgery and Psychiatry (2022)
4. Self-Reported Safety of the Bbibp-Corv (Sinopharm) Covid-19 Vaccine Among Iranian People With Multiple Sclerosis, Human Vaccines and Immunotherapeutics (2022)
5. Comparing the Consequences of Covid-19 Vaccination Between Central Nervous System (Cns) Demyelinating Diseases and Other Neurological Disorders, Vaccine (2024)
6. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
7. Covid-19 Susceptibility and Outcomes Among Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
8. Efficacy and Safety of an Inactivated Virus-Particle Vaccine for Sars-Cov-2, Biv1-Coviran: Randomised, Placebo Controlled, Double Blind, Multicentre, Phase 3 Clinical Trial, BMJ (2023)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (16)
Masoud Etemadifar (9)
Other Related Docs
9. Association of Prior Covid‑19 Infection With Risk of Breakthrough Infection Following Vaccination: A Cohort Study in Isfahan, Iran, International Journal of Preventive Medicine (2024)
10. Risk and Severity of Sars-Cov-2 Reinfection Among Patients With Multiple Sclerosis Vs. the General Population: A Population-Based Study, BMC Neurology (2022)
11. Multiple Sclerosis (Ms) and Neuromyelitis Optica Spectrum Disorder (Nmosd) Following Covid-19 Vaccines: A Systematic Review, Revue Neurologique (2023)
12. Does Covid-19 Increase the Long-Term Relapsing-Remitting Multiple Sclerosis Clinical Activity? a Cohort Study, BMC Neurology (2022)
13. Third Covid-19 Vaccine Dose for People With Multiple Sclerosis Who Did Not Seroconvert Following Two Doses of Bbibp-Corv (Sinopharm) Inactivated Vaccine: A Pilot Study on Safety and Immunogenicity, Frontiers in Immunology (2023)
14. Covid-19 Vaccine Boosters: The Good, the Bad, and the Ugly, Vaccines (2021)
15. Sars-Cov-2 Serology Among People With Multiple Sclerosis on Disease-Modifying Therapies After Bbibp-Corv (Sinopharm) Inactivated Virus Vaccination: Same Story, Different Vaccine, Multiple Sclerosis and Related Disorders (2022)
16. The Effect of Covid-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran, Iranian Journal of Public Health (2022)
17. Multiple Sclerosis Relapse After Covid-19 Vaccination: A Case Report-Based Systematic Review, Journal of Clinical Neuroscience (2022)
18. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
19. Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran, Vaccines (2022)
20. Convalescent Plasma Therapy for Covid-19: Lessons From Sars-Cov, Mers-Cov, and H1n1 Infection, Acta Medica Indonesiana (2021)
21. Vaccine-Associated Complications: A Comparative Multicenter Evaluation Among Dental Practitioners and Dental Students—Which Candidate Vaccine Is More Safe in Sars Cov Ii, Gam-Covid-Vac (Sputnik V), Chadox1 Ncov-19 (Astrazeneca), Bbv152 (Covaxin), or Bbibp-Corv(Sinopharm)?, Maxillofacial Plastic and Reconstructive Surgery (2022)
22. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic Covid-19 in 2020 and 2021, JAMA (2022)
23. Covid-19 Breakthrough Infections Among Patients With Cancer Receiving Sinopharm Bibp Vaccine, International Journal of Cancer Management (2022)
24. Outcome of Covid-19 Infection in Multiple Sclerosis Patients Receiving Disease-Modifying Therapies, Journal of Research in Medical Sciences (2021)
25. Risk Factors for the Mortality in Hospitalized Patients With Covid-19: A Brief Report, Iranian Journal of Medical Sciences (2021)
26. Importance of the Covid-19 Vaccine Booster Dose in Protection and Immunity, Vaccines (2022)
27. The Effect of Bortezomib Regimen on Multiple Myeloma Patients Infected With Covid-19, Middle East Journal of Cancer (2023)
28. Sars-Cov-2 and Stroke Characteristics: A Report From the Multinational Covid-19 Stroke Study Group, Stroke (2021)
29. Covid‑19’S Effect in Pregnancy and Vertical Transmission: A Systematic Review, International Journal of Preventive Medicine (2024)
30. Cancer Patients’ Challenges During Covid-19 Pandemic: An Approach to Decision-Making in Management and Policy-Making, Archives of Clinical Infectious Diseases (2021)
31. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
32. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
33. Lactate Dehydrogenase to Albumin Ratio As a Predictive Factor of Covid-19 Patients’ Outcome; a Cross-Sectional Study, Archives of Academic Emergency Medicine (2022)
34. Comparison of Machine-Learning Algorithms Efficiency to Build a Predictive Model for Mortality Risk in Covid-19 Hospitalized Patients, Koomesh (2022)
35. Sars-Cov-2 (Covid-19): New Discoveries and Current Challenges, Applied Sciences (Switzerland) (2020)
36. Monitoring and Active Surveillance of Adverse Events Following the Booster Dose of Azd1222 Vaccine in People Vaccinated With Sinopharm Bbibp-Corv: A Cohort Study, BMC Public Health (2025)
37. Outcomes of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase, Stroke (2022)
38. Covid-19 Vaccines and Patients With Multiple Sclerosis: Willingness, Unwillingness and Hesitancy: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
39. Covid-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in Covid-19-Vaccinated Patients: A Multicenter Comparative Cohort Study, Arthroplasty Today (2022)
40. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of Covid-19 in Multiple Sclerosis: A Menactrims Registry Based Study, Multiple Sclerosis and Related Disorders (2024)
41. Survival Analysis for Predictive Factors of Delay Vaccination in Iranian Children, International Journal of Preventive Medicine (2015)
42. Aspects of Epidemiology, Pathology, Virology, Immunology, Transmission, Prevention, Prognosis, Diagnosis, and Treatment of Covid.19 Pandemic: A Narrative Review, International Journal of Preventive Medicine (2021)
43. Cerebral Venous Sinus Thrombosis Associated With Sars-Cov-2; a Multinational Case Series, Journal of the Neurological Sciences (2020)
44. Epidemiological Features of Covid-19 in Iran, Journal of Research in Medical Sciences (2022)
45. Efficacy and Side Effects of Sputnik V, Sinopharm and Astrazeneca Vaccines to Stop Covid-19; a Review and Discussion, Immunopathologia Persa (2021)
46. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
47. Covid-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran, Vaccines (2022)
48. The Seroprevalence and Seropositivity of Sars-Cov-2 Among Healthcare Workers During the Third Pandemic Wave, Antibodies (2023)
49. Covid-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight With No Bystander Effect?, Multiple Sclerosis and Related Disorders (2021)
50. Covid-19 Infection and Hospitalization Rate in Iranian Multiple Sclerosis Patients: What We Know by May 2021, Multiple Sclerosis and Related Disorders (2022)